Multidimensional biomarkers for multiple system atrophy: an update and future directions.

Area of Science:

• Neurodegenerative Diseases
• Biomarker Discovery
• Translational Medicine

Background:

• Multiple system atrophy (MSA) is a severe, progressive neurodegenerative disorder with limited diagnostic and prognostic tools.
• The urgent need for reliable biomarkers in MSA is critical for clinical management and therapeutic development.
• Current clinical practice lacks sufficient validated biomarkers for effective MSA diagnosis and monitoring.

Purpose of the Study:

• To systematically review and summarize recent advancements in multidimensional biomarkers for Multiple System Atrophy (MSA).
• To cover a comprehensive range of biomarker types, including those from biological fluids, tissues, gut microbiota, and advanced imaging techniques.
• To discuss future research avenues and strategies for implementing novel MSA biomarkers into clinical practice.

Main Methods:

• Systematic literature review of recent research on MSA biomarkers.
• Categorization of biomarkers into fluid-based, tissue-based, gut microbiota, and imaging modalities.
• Analysis of the current status and future potential of identified biomarkers.

Main Results:

• Significant progress has been made in identifying potential biomarkers across various dimensions for MSA.
• Fluid biomarkers (e.g., CSF, blood), tissue analysis, gut microbiome profiling, and specific imaging techniques show promise.
• Despite advancements, few biomarkers are currently implemented in routine clinical settings for MSA.

Conclusions:

• Multidimensional biomarkers hold significant potential for improving MSA diagnosis, prognosis, and therapeutic monitoring.
• Further research and validation are essential to translate promising biomarkers into clinical application.
• Future efforts should focus on integrating diverse biomarker data and promoting their clinical utility for MSA patients.